# FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

> **NCT02641639** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mateon Therapeutics** · enrollment: 70 (actual)

## Conditions studied

- Platinum Resistant Ovarian Cancer

## Interventions

- **DRUG:** Fosbretabulin tromethamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02641639
- **Lead sponsor:** Mateon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** The study was terminated early due to the lack of efficacy and the study sponsor's decision to no longer continue the study
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641639, "FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02641639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*